September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Segregation analysis revealed causative mutations in an Oculocutaneous Albinism (OCA) patient
Author Affiliations & Notes
  • Xinjing Wang
    NEI, Bethesda, Maryland, United States
  • Jackson Gao
    NEI, Bethesda, Maryland, United States
  • Keith Wetherby
    NEI, Bethesda, Maryland, United States
  • CHIMERE ROBERSON
    NEI, Bethesda, Maryland, United States
  • MELISSA REEVES
    NEI, Bethesda, Maryland, United States
  • ALEXANDRA GARAFALO
    NEI, Bethesda, Maryland, United States
  • REBECCA PARRISH
    NEI, Bethesda, Maryland, United States
  • ANNETTE YIM
    NEI, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Xinjing Wang, None; Jackson Gao, None; Keith Wetherby, None; CHIMERE ROBERSON, None; MELISSA REEVES, None; ALEXANDRA GARAFALO, None; REBECCA PARRISH, None; ANNETTE YIM, None
  • Footnotes
    Support  NEI intramural programs
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 6581. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xinjing Wang, Jackson Gao, Keith Wetherby, CHIMERE ROBERSON, MELISSA REEVES, ALEXANDRA GARAFALO, REBECCA PARRISH, ANNETTE YIM; Segregation analysis revealed causative mutations in an Oculocutaneous Albinism (OCA) patient
      . Invest. Ophthalmol. Vis. Sci. 2016;57(12):6581.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Oculocutaneous albinism is composed of autosomal recessive disorders of melanin biosynthesis characterized by hypopigmentation of hair, skin and eyes. OCA causative mutations have been found in several responsible genes. We here analyzed our OCA patients for an OCA2 gene exon 7 deletion to evaluate the frequency of this deletion in our patient population.

Methods : We studied 100 patients referred with the clinical diagnosis of OCA. Total genomic DNA was extracted from blood samples obtained from OCA patients. The DNA was first screened for mutations in the TYR gene and/or OCA2 gene by direct sequencing. In addition, we performed OCA 2 gene exon 7 deletion studies using the long range PCR kit developed by Takara.

Results : In the patients without two mutations or two mutation candidates in either TYR gene or OCA2 gene, we analyzed their DNA for the potential exon 7 deletion. We found none of these patients bearing the common exon 7 deletion. However, we found a patient with one known OCA2 gene mutation, and one variant with unknown significant but likely pathogenic, p.R305W, also carrying the exon 7 deletion in heterozygosity. Moreover, we found that his mom is positive for the p.R305W in a homozygous status and the exon 7 deletion in a heterozygous status. We excluded another four OCA patients who bear the p.R305W from possibly carrying the exon 7 deletion.

Conclusions : Our analyses provide genetic evidence and molecular conformation for the causative mutations in this cohort of OCA patients. For the patients without a second mutation, we explored the likelihood of the most common exonic deletion, the 2.7 kb exon 7 deletion, in the OCA2 gene for the genotype-phenotype correlation. For the controversial variant, p.R305W, we suggest an unlikely pathogenic status for molecular diagnosis.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×